Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3561 - How Spanish medical oncologists manage breakthrough pain? A national study

Date

10 Sep 2017

Session

Poster display session

Presenters

Enrique Aranda

Citation

Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388

Authors

E. Aranda1, C. Camps Herrero2, P. Khosravi3, M. Feyjoo4, A. Anton Torres5, P. Gascon6, J. Garcia Foncillas7, E. Diaz Rubio8, V. Guillem Porta9, A. Carrato10, M. Constenla Figueiras11, J.J. Cruz Hernandez12, R. López13

Author affiliations

  • 1 Medical Oncology, University Hospital Reina Sofia, 14004 - Cordoba/ES
  • 2 Medical Oncology, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 3 Oncology Department, Hospital Universitario de Torrejón, 28850 - Torrejón de Ardoz/ES
  • 4 Oncology Department, Hospital Sanitas La Moraleja, 28050 - Madrid/ES
  • 5 Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 6 Division Of Medical Oncology, Institut Clinic Malalties Hemato-Oncològiques (ICMHO), 08036 - Barcelona/ES
  • 7 Cancer Institute, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 8 Medical Oncology, Hospital Clinico Universitario San Carlos. CIBERONC Instituto de Salud Carlos III, 28040 - Madrid/ES
  • 9 Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 10 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 11 Medical Oncology, Hospital Provincial de Pontevedra, 36001 - Pontevedra/ES
  • 12 Oncología Médica, Hospital Universitario de Salamanca, 37007 - Salamanca/ES
  • 13 Medical Oncology Department, Hospital Clínico de Santiago, Santiago de Compostela/ES
More

Resources

Abstract 3561

Background

Many cancer patients experience transient exacerbations of severe pain, known as breakthroughcancer pain (BTcP), a complex pain state that negatively impacts patients’ quality of life. We evaluated the knowledge of BTcP management according to the Spanish Society of Medical Oncology (SEOM) clinical practice guideline.

Methods

Fundación ECO (Foundation for Excellence and Quality in Oncology) conducted a survey regarding knowledge of managing BTcP focusing on: awareness of SEOM guidelines, agreement with recommendations, and implementation in clinical practice.

Results

A total of 83 oncologists responded: 65% were female, mean age was 40-year-old and mean time in practice was 13 years. Overall, 82% were aware of guidelines and the agreement with recommendations ranged from 99-100%. Regarding implementation, 87.6% declared full compliance, nonetheless adherence in clinical practice ranged from 30.1% to 86.7% for documentation of BTcP episodes in medical records, and 75.9% to 91.6% for therapeutic management.100% of oncologists agreed on the prescription of specific medication for BTcP and most of them (91.6%) that rapid onset fentanyl formulations should be considered the first line of treatment.rnTable:

1587P

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
CPG AWARENESS 81.93% (68/83)AGREEMENTIMPLEMENTATION (in medical records)IMPLEMENTATION (ranked drug of choice characteristics)
SEOM 97.1%100% documentationEpisodes (n) 73.5%Rapid onset
ESMO 63.2%99% best evidencePain intensity 66.3%High potency
NCCN 58.8%99% specific medicationDuration 45.8%Short duration
Instit 19.1%99% fentanyl 1st choiceTime to peak 30.1%Route of administration
Other 7.3%rnTriggers 75.9%Ease of use
rnrnRelief strategies 73.5%Minimum side effects
rnrnEtiopathogenia 86.7%rn
rn

Conclusions

Our results support efforts and targeted education of medical oncologists in BTcP management. However, our study raises concerns about guidelines dissemination deficiencies as well as vague statements that underscore a need for more effective dissemination policy and more effective detailed recommendations.

Clinical trial identification

Legal entity responsible for the study

Fundación ECO (Foundation for Excellence and Quality in Oncology)

Funding

Kyowa Kirin Farmacéutica, S.L.U.

Disclosure

E. Aranda: Consulting or Advisory Role - Amgen; Bayer; Celgene; Merck Sharp & Dohme; Roche; Sanofi P. Gascon: Consulting or Advisory Role - Ability Pharma (Inst) Research Funding - Ability Pharma (Inst) E. Diaz Rubio: Consulting or advisory role or speaker bureau: Roche, Merck Serono, Amgen, Bayer, MSD, Genomica, Servier. A. Carrato: Consulting or Advisory Role - Amgen; Baxalta; Bayer; Bristol-Myers Squibb; Celgene; Merck; MSD Oncology; Roche; Sanofi Speakers\' Bureau - Amgen; Bayer; Celgene; Merck Travel, Accommodations, Expenses - Celgene; Merck; Roche All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.